Delayed pulsing of quiescent and activated CLL cultures with selective inhibitors of BCL2 or survivin revealed selective targeting of noncycling and cycling populations, respectively, raising implications for therapy. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.